1. Scrip
  2. >>Business

Key Wins In US By Indian Firms - Keep An Eye On These In 2019

 
• By Anju Ghangurde

2018 saw front-line Indian companies receive some key product approvals in the US or sew up large or niche M&A transactions there. How these play out could have a material impact on the growth outlook of these firms in 2019. 

Dollar - Rupee
KEY PRODUCT APPROVALS AND DEALS IN THE US COULD SHAPE 2019 FOR LARGE INDIAN FIRMS

It has been an eventful 2018 for India Pharma Inc in the US, to say the least. Among some interesting wins during the year were high profile product launches, including a partnered biosimilar from Biocon Ltd.’s stable that hit the US market, and the largest out-bound M&A deal by an Indian pharma company, which saw Aurobindo Pharma Ltd. snap up certain parts of Sandoz International GMBH’s US portfolio.

The impact of some of these events, such as the Aurobindo-Sandoz deal or then Sun Pharmaceutical Industries Ltd.’s launch...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Pipeline Watch: Ten Approvals And Two Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Merck & Co’s Verona acquisition; venture funding plummets in Q2; how Teva is expanding innovation; Apogee’s Phase II eczema win; and a look at India’s wave of licensing.

Capricor Gets Complete Response For DMD Cell Therapy

 
• By Joseph Haas

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.